Start here if you're new
what it is
REE builds electric truck chassis and wheel modules for commercial vehicles.
how it gets paid
Last year Ree Automotive made $183K in revenue. REEcorner module sales was the main engine at $52K, or 28% of sales.
what just happened
REE's latest print put $183K in revenue against a -$0.81 EPS loss.
At a glance
n/a balance sheet
-$7.01 fy2024 eps est
$0M fy2024 rev est
n/a operating margin
1.7 beta
What they do
REE builds electric truck chassis and wheel modules for commercial vehicles.
REEcorner puts steering, braking, suspension, power, and control inside the wheel corner. That is 1 module vs. a normal setup with many separate parts. If your fleet is designed around that layout, changing vendors means reworking the whole vehicle.
How they make money
$183K
annual revenue
REEcorner module sales
$52K
REEplatform sales
$41K
P7-S Strip Chassis
$34K
P7-C Chassis Cab
$28K
P7-B Box Truck
$28K
The products that matter
modular EV platform system
REEcorner
$207K trailing revenue tied to the broader platform story
it is the core x-by-wire architecture, but the business built around it produced just $207K in trailing revenue. that's proof of technical ambition, not proof of product-market fit.
commercialization watch
Key numbers
$183K
annual revenue
That is smaller than the $15M debt pile. The business is still tiny, and the bills are not.
$15M
debt load
Debt is about 83% of the $18M market cap. Lenders matter more than customers here.
43,239.9%
operating loss rate
That means the company lost far more than it sold. Break-even is not close.
1.7
beta
That is 70% more swingy than a normal stock. Your portfolio feels the market harder here.
Financial health
n/a
strength
- balance sheet grade n/a
- price stability 5 / 100
- long-term debt $15M (45% of capital)
n/a — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for REE right now.
source: institutional data · return history unavailable
What just happened
missed estimates
REE's latest print put $183K in revenue against a -$0.81 EPS loss.
Gross margin, or profit after direct costs, was -1,n/a. Sales were tiny, and the loss line stayed large.
$183K
revenue
-$0.81
eps
n/a
gross margin
gross margin
The n/a gross margin is the red flag. Direct costs were about 20 times revenue.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk here is Nasdaq delisting from a sub-$1 share price. for REE, that is not paperwork. it is a financing and credibility problem.
high
Nasdaq delisting risk
the stock trades at $0.68, below the $1 minimum bid threshold. management has a limited window to fix that.
a delisting would likely reduce liquidity and make future capital raises harder for an already fragile story.
high
commercialization failure
trailing revenue is just $207K and annual revenue rounded to $0M. that means the technology still has not crossed into meaningful market adoption.
if orders do not materialize, the equity case goes from speculative to optionality-only very quickly.
med
debt versus tiny revenue
long-term debt is $15M, or 45% of capital. against $207K in trailing sales, that is a heavy load for a business without scale.
capital structure stress can force unattractive financing decisions long before the technology gets a fair trial.
med
established supplier competition
REE is trying to win in a market where incumbents already have manufacturing scale, customer relationships, and balance sheets that do not depend on one breakthrough.
even if the technology works, converting that into volume sales is harder when customers already know the other vendors.
between a $0.68 share price, $207K in trailing revenue, and $15M of long-term debt, the risk picture is simple: this company needs commercial proof fast.
source: institutional data · regulatory filings · risk analysis
Pay attention to
listing risk
sub-$1 compliance path
the stock is at $0.68. until that changes, every other update competes with a basic exchange-listing problem.
calendar
march 24, 2026 earnings call
listen for cash commentary, compliance strategy, and whether management says anything concrete on production timing.
metric
revenue above the current $207K base
this story does not need perfect margins yet. it needs revenue that starts looking real.
trend
proof of a production partner or order
one firm commercial deal would change the tone. until then, the market is being asked to fund a possibility.
Analyst rankings
coverage
thin
institutional ranking data is limited. in human-speak, this sits outside the well-covered part of the market.
estimate quality
low confidence
when revenue is $207K and commercialization is still the thesis, small estimate changes do not tell you much.
source: institutional data
Institutional activity
institutional ownership data for REE is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$1
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive